Q-omics provides the consensus-scored PLEKHA5 profile across patient tissues and cancer cell-line models. PLEKHA5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, PLEKHA5 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, PLEKHA5 RNA expression shows 20,329 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight PAAD, KICH, and THYM as cancer lineages where PLEKHA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLEKHA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLEKHA5 survival associations across molecular data types. PLEKHA5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLEKHA5 RNA expression–survival associations across cancer types. High PLEKHA5 expression shows unfavorable associations in PAAD, MESO, ACC and HNSC, but favorable associations in LAML and LUSC. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for PLEKHA5 RNA expression.
This table summarizes PLEKHA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PLEKHA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLEKHA5 shows lower tumor expression in KICH and higher tumor expression in LIHC, CHOL, LUSC, LUAD and COAD. The KICH box plot shows higher PLEKHA5 RNA expression in normal versus tumor tissue (log2 FC = −1.524, t-test p < 0.001).
This table shows molecular features associated with PLEKHA5 in patient tissues and cancer cell lines. In patient samples, PLEKHA5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLEKHA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
